A Randomized, Double-blinded, and Placebo-controlled Phase I/II Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
Phase of Trial: Phase I/II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs AK-101 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Akeso Biopharma
- 19 Nov 2019 Status changed from recruiting to completed.
- 21 Mar 2018 New trial record
- 22 Dec 2017 According to an Akeso Biopharma media release, this trial has been launched at the Chinese Academy of Medical Sciences Peking Union Medical College Hospital, and has begun screening and enrolling patients.